Pain Management of Vulvodynia and Dyspareunia

Abstract

Dr. Gevirtz is Associate Professor of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, and Medical Director, Somnia Pain Management, 627 W Harrison St, New York, NY 10528; E-mail: [email protected]. All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Dr. Gevirtz has disclosed that use of botulinum toxin A, tricyclic antidepressants (nortriptyline, desipramine), pregabalin, lidocaine topical ointment, and lidocaine/prilocaine cream for treatment of vulvodynia and dyspareunia as discussed in this article has not been approved by the U.S. Food and Drug Administration. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed answer form, answering at least seven of the 10 quiz questions correctly. This activity expires on November 14, 2013.